These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37870738)

  • 21. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
    Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
    Corcoran RB; Ebi H; Turke AB; Coffee EM; Nishino M; Cogdill AP; Brown RD; Della Pelle P; Dias-Santagata D; Hung KE; Flaherty KT; Piris A; Wargo JA; Settleman J; Mino-Kenudson M; Engelman JA
    Cancer Discov; 2012 Mar; 2(3):227-35. PubMed ID: 22448344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Combinatorial Strategy for Targeting
    Ghosh C; Kumar S; Kushchayeva Y; Gaskins K; Boufraqech M; Wei D; Gara SK; Zhang L; Zhang YQ; Shen M; Mukherjee S; Kebebew E
    Clin Cancer Res; 2020 Apr; 26(8):2022-2036. PubMed ID: 31937621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.
    Preto A; Figueiredo J; Velho S; Ribeiro AS; Soares P; Oliveira C; Seruca R
    J Pathol; 2008 Feb; 214(3):320-7. PubMed ID: 18098337
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Tan J; Liu R; Zhu G; Umbricht CB; Xing M
    Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15846-15851. PubMed ID: 32561648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway.
    Nakamura Y; Hattori N; Iida N; Yamashita S; Mori A; Kimura K; Yoshino T; Ushijima T
    Cancer Lett; 2017 Aug; 402():100-109. PubMed ID: 28576751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAF V600E is a determinant of sensitivity to proteasome inhibitors.
    Zecchin D; Boscaro V; Medico E; Barault L; Martini M; Arena S; Cancelliere C; Bartolini A; Crowley EH; Bardelli A; Gallicchio M; Di Nicolantonio F
    Mol Cancer Ther; 2013 Dec; 12(12):2950-61. PubMed ID: 24107445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF
    Trivieri N; Pracella R; Cariglia MG; Panebianco C; Parrella P; Visioli A; Giani F; Soriano AA; Barile C; Canistro G; Latiano TP; Dimitri L; Bazzocchi F; Cassano D; Vescovi AL; Pazienza V; Binda E
    J Exp Clin Cancer Res; 2020 Dec; 39(1):285. PubMed ID: 33317591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAF
    Feng D; Qin B; Pal K; Sun L; Dutta S; Dong H; Liu X; Mukhopadhyay D; Huang S; Sinicrope FA
    Oncogene; 2019 Oct; 38(41):6752-6766. PubMed ID: 31406255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
    Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
    Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
    Mao M; Tian F; Mariadason JM; Tsao CC; Lemos R; Dayyani F; Gopal YN; Jiang ZQ; Wistuba II; Tang XM; Bornman WG; Bollag G; Mills GB; Powis G; Desai J; Gallick GE; Davies MA; Kopetz S
    Clin Cancer Res; 2013 Feb; 19(3):657-67. PubMed ID: 23251002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications.
    Liu W; Stachura P; Xu HC; Umesh Ganesh N; Cox F; Wang R; Lang KS; Gopalakrishnan J; Häussinger D; Homey B; Lang PA; Pandyra AA
    J Exp Clin Cancer Res; 2020 Feb; 39(1):38. PubMed ID: 32085796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic
    Miyauchi S; Shien K; Takeda T; Araki K; Nakata K; Miura A; Takahashi Y; Kurihara E; Ogoshi Y; Namba K; Suzawa K; Yamamoto H; Okazaki M; Soh J; Tomida S; Yamane M; Sakaguchi M; Toyooka S
    Anticancer Res; 2020 May; 40(5):2667-2673. PubMed ID: 32366411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside.
    Choi HJ; Kim TY; Chung N; Yim JH; Kim WG; Kim JA; Kim WB; Shong YK
    J Endocrinol; 2011 Oct; 211(1):79-85. PubMed ID: 21795305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRAF as a target for cancer therapy.
    Dienstmann R; Tabernero J
    Anticancer Agents Med Chem; 2011 Mar; 11(3):285-95. PubMed ID: 21426297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.
    Coffee EM; Faber AC; Roper J; Sinnamon MJ; Goel G; Keung L; Wang WV; Vecchione L; de Vriendt V; Weinstein BJ; Bronson RT; Tejpar S; Xavier RJ; Engelman JA; Martin ES; Hung KE
    Clin Cancer Res; 2013 May; 19(10):2688-98. PubMed ID: 23549875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells.
    Herr R; Köhler M; Andrlová H; Weinberg F; Möller Y; Halbach S; Lutz L; Mastroianni J; Klose M; Bittermann N; Kowar S; Zeiser R; Olayioye MA; Lassmann S; Busch H; Boerries M; Brummer T
    Cancer Res; 2015 Jan; 75(1):216-29. PubMed ID: 25381152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-Invasive Glutamine PET Reflects Pharmacological Inhibition of BRAF
    Schulte ML; Hight MR; Ayers GD; Liu Q; Shyr Y; Washington MK; Manning HC
    Mol Imaging Biol; 2017 Jun; 19(3):421-428. PubMed ID: 27770401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specific activation of glycolytic enzyme enolase 2 in BRAF V600E-mutated colorectal cancer.
    Yukimoto R; Nishida N; Hata T; Fujino S; Ogino T; Miyoshi N; Takahashi H; Uemura M; Satoh T; Hirofumi Y; Mizushima T; Doki Y; Eguchi H
    Cancer Sci; 2021 Jul; 112(7):2884-2894. PubMed ID: 33934428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
    Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
    BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.